FDA approves once-weekly Sogroya® for the treatment of children living with growth hormone deficiency
The Pharma Data
APRIL 28, 2023
FDA approves once-weekly Sogroya® for the treatment of children living with growth hormone deficiency Novo Nordisk announced today that the U.S. years and older who have growth failure due to inadequate secretion of endogenous growth hormone. cm/year vs. 11.7 cm/year, respectively). cm/year vs. 11.7 cm/year, respectively).
Let's personalize your content